DK0790986T3 - Anilinderivater - Google Patents
AnilinderivaterInfo
- Publication number
- DK0790986T3 DK0790986T3 DK95936044T DK95936044T DK0790986T3 DK 0790986 T3 DK0790986 T3 DK 0790986T3 DK 95936044 T DK95936044 T DK 95936044T DK 95936044 T DK95936044 T DK 95936044T DK 0790986 T3 DK0790986 T3 DK 0790986T3
- Authority
- DK
- Denmark
- Prior art keywords
- pct
- date
- sec
- pub
- aniline
- Prior art date
Links
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 title 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000002490 anilino group Chemical class [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9422866A GB9422866D0 (en) | 1994-11-12 | 1994-11-12 | Aniline derivatives |
| GBGB9507308.6A GB9507308D0 (en) | 1995-04-07 | 1995-04-07 | Aniline derivatives |
| PCT/GB1995/002606 WO1996015118A1 (en) | 1994-11-12 | 1995-11-08 | Aniline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0790986T3 true DK0790986T3 (da) | 1999-09-13 |
Family
ID=26305974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK95936044T DK0790986T3 (da) | 1994-11-12 | 1995-11-08 | Anilinderivater |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5821246A (OSRAM) |
| EP (1) | EP0790986B1 (OSRAM) |
| JP (1) | JP4011109B2 (OSRAM) |
| AT (1) | ATE175962T1 (OSRAM) |
| AU (1) | AU703328B2 (OSRAM) |
| CA (1) | CA2200871C (OSRAM) |
| DE (1) | DE69507505T2 (OSRAM) |
| DK (1) | DK0790986T3 (OSRAM) |
| ES (1) | ES2128092T3 (OSRAM) |
| FI (1) | FI119933B (OSRAM) |
| IL (1) | IL115959A (OSRAM) |
| MX (1) | MX9702956A (OSRAM) |
| NO (1) | NO307178B1 (OSRAM) |
| NZ (1) | NZ294917A (OSRAM) |
| TW (1) | TW321649B (OSRAM) |
| WO (1) | WO1996015118A1 (OSRAM) |
Families Citing this family (134)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| TW321649B (OSRAM) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| EP0824525B1 (en) * | 1995-04-27 | 2001-06-13 | AstraZeneca AB | Quinazoline derivatives |
| GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
| GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508537D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| US5760041A (en) * | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| KR19990082463A (ko) | 1996-02-13 | 1999-11-25 | 돈 리사 로얄 | 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체 |
| GB9603097D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| AU719327B2 (en) | 1996-03-05 | 2000-05-04 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
| EA001595B1 (ru) | 1996-04-12 | 2001-06-25 | Варнер-Ламберт Компани | Необратимые ингибиторы тирозинкиназ |
| GB9607729D0 (en) * | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
| DE69717627T2 (de) | 1996-06-27 | 2003-09-18 | Janssen Pharmaceutica N.V., Beerse | N-4-(heteroarylmethyl)phenyl-heteroarylaminderivate |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| DE19642529A1 (de) | 1996-10-15 | 1998-04-16 | Bayer Ag | Aminophenolderivate |
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| KR100520401B1 (ko) | 1997-04-25 | 2005-10-12 | 얀센 파마슈티카 엔.브이. | 파네실 트랜스퍼라제 억제작용을 갖는 퀴나졸리논 |
| PT980244E (pt) * | 1997-05-06 | 2003-10-31 | Wyeth Corp | Utilizacao de compostos de quinazolina para o tratamento da doenca policistica renal |
| US5929080A (en) * | 1997-05-06 | 1999-07-27 | American Cyanamid Company | Method of treating polycystic kidney disease |
| ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) * | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| US6251912B1 (en) | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
| DE69838172T2 (de) | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
| US6323209B1 (en) | 1997-11-06 | 2001-11-27 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
| GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9800575D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| AU759255B2 (en) | 1998-01-29 | 2003-04-10 | Amgen, Inc. | PPAR-gamma modulators |
| US6583157B2 (en) | 1998-01-29 | 2003-06-24 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| US6706721B1 (en) * | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
| AU4317399A (en) * | 1998-05-28 | 1999-12-13 | Parker Hughes Institute | Quinazolines for treating brain tumor |
| US6384223B1 (en) | 1998-07-30 | 2002-05-07 | American Home Products Corporation | Substituted quinazoline derivatives |
| US6258820B1 (en) | 1999-03-19 | 2001-07-10 | Parker Hughes Institute | Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines |
| US7049410B2 (en) * | 1999-05-14 | 2006-05-23 | Majumdar Adhip P N | Antibodies to a novel EGF-receptor related protein (ERRP) |
| WO2000069909A1 (en) | 1999-05-14 | 2000-11-23 | The United States Of America Through The Department Of Veterans Affairs | Isolation and characterization of epidermal growth factor related protein |
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| WO2001000579A1 (en) * | 1999-06-30 | 2001-01-04 | Tularik Inc. | COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY |
| US6933299B1 (en) | 1999-07-09 | 2005-08-23 | Smithkline Beecham Corporation | Anilinoquinazolines as protein tyrosine kinase inhibitors |
| JP2003504363A (ja) | 1999-07-09 | 2003-02-04 | グラクソ グループ リミテッド | プロテインチロシンキナーゼ阻害剤としてのアニリノキナゾリン類 |
| CZ20021009A3 (cs) * | 1999-09-21 | 2002-06-12 | Astrazeneca Ab | Deriváty chinazolinu, způsob jejich přípravy a jejich pouľití jako léčiv |
| EE200200149A (et) | 1999-09-21 | 2003-04-15 | Astrazeneca Ab | Kinasoliinühendid ja neid sisaldavad ravimkoostised |
| IL149034A0 (en) | 1999-11-05 | 2002-11-10 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
| UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| US7087613B2 (en) * | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
| SI1274692T1 (sl) * | 2000-04-07 | 2006-12-31 | Astrazeneca Ab | Kinazolinske spojine |
| AU6118001A (en) | 2000-05-03 | 2001-11-12 | Tularik Inc | Combination therapeutic compositions and methods of use |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| JP4044839B2 (ja) * | 2000-06-22 | 2008-02-06 | ファイザー・プロダクツ・インク | 異常細胞増殖を治療するための置換２環式誘導体 |
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| JP4102185B2 (ja) * | 2000-06-30 | 2008-06-18 | グラクソ グループ リミテッド | キナゾリンジトシル酸塩化合物 |
| KR100821446B1 (ko) | 2000-08-21 | 2008-04-10 | 아스트라제네카 아베 | 퀴나졸린 유도체 |
| EP1326859A1 (en) * | 2000-10-13 | 2003-07-16 | AstraZeneca AB | Quinazoline derivatives with anti-tumour activity |
| AU2002217999A1 (en) | 2000-11-01 | 2002-05-15 | Cor Therapeutics, Inc. | Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| JP2002293773A (ja) * | 2001-03-30 | 2002-10-09 | Sumika Fine Chemicals Co Ltd | キナゾリン誘導体の製造方法 |
| EP1408980A4 (en) | 2001-06-21 | 2004-10-20 | Ariad Pharma Inc | NEW QUINAZOLINES AND THEIR USE |
| BR0213842A (pt) * | 2001-11-03 | 2004-08-31 | Astrazeneca Ab | Derivado de quinazolina ou um sal deste farmaceuticamente aceitável, processo para a preparação do mesmo, composição farmacêutica, e, uso do derivado de quinazolina ou de um sal deste farmaceuticamente aceitável |
| GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
| CA2462149C (en) * | 2001-11-30 | 2010-06-22 | Pfizer Products Inc. | Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth |
| UA82058C2 (uk) | 2001-12-24 | 2008-03-11 | Астразенека Аб | Заміщені похідні хіназоліну як інгібітори ауроракінази, спосіб їх одержання, фармацевтична композиція на їх основі |
| CN1627944A (zh) | 2002-01-17 | 2005-06-15 | 神经能质公司 | 取代的喹唑啉－4－基胺类似物作为辣椒辣素调节剂 |
| TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| JP4703183B2 (ja) | 2002-07-15 | 2011-06-15 | シンフォニー エボルーション， インク． | 受容体型キナーゼモジュレーターおよびその使用方法 |
| US7488823B2 (en) | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
| US7528121B2 (en) | 2002-12-24 | 2009-05-05 | Astrazeneca Ab | Phosphonooxy quinazoline derivatives and their pharmaceutical use |
| WO2004069145A2 (en) * | 2003-02-07 | 2004-08-19 | Dr. Reddy's Laboratories Ltd. | Anticancer compounds, process for their preparation and pharmaceutical compositions containing them |
| CA2522079A1 (en) * | 2003-04-16 | 2004-11-04 | Astrazeneca Ab | Quinazoline derivatives for treatment of cancer |
| GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
| GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
| EP1636195A1 (en) * | 2003-05-27 | 2006-03-22 | Pfizer Products Inc. | Quinazolines and pyrido[3,4-d]pyrimidines as receptor tyrosine kinase inhibitors |
| US20060135541A1 (en) * | 2003-06-02 | 2006-06-22 | Astrazeneca Ab | (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer |
| AU2004261477A1 (en) * | 2003-07-29 | 2005-02-10 | Astrazeneca Ab | Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors |
| GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
| NZ545459A (en) * | 2003-08-14 | 2009-12-24 | Array Biopharma Inc | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| WO2005028470A1 (en) * | 2003-09-19 | 2005-03-31 | Astrazeneca Ab | Quinazoline derivatives |
| PL1667992T3 (pl) * | 2003-09-19 | 2007-05-31 | Astrazeneca Ab | Pochodne chinazoliny |
| US20070043010A1 (en) * | 2003-09-25 | 2007-02-22 | Astrazeneca Uk Limited | Quinazoline derivatives |
| ES2651730T3 (es) | 2003-09-26 | 2018-01-29 | Exelixis, Inc. | Moduladores c-Met y métodos de uso |
| US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| EP1684762A4 (en) | 2003-11-13 | 2009-06-17 | Ambit Biosciences Corp | UREA DERIVATIVES AS MODULATORS OF KINASE |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| UA82577C2 (en) | 2003-12-23 | 2008-04-25 | Пфайзер Инк. | Quinoline derivatives |
| US20080242681A1 (en) * | 2004-01-22 | 2008-10-02 | Altana Pharma Ag | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors |
| EP1755394A4 (en) * | 2004-04-16 | 2009-08-05 | Smithkline Beecham Corp | METHOD OF TREATING CANCER |
| RS52119B (sr) * | 2004-05-06 | 2012-08-31 | Warner-Lambert Company Llc | 4-fenilamino-hinazolin-6-il-amidi |
| JP5065017B2 (ja) * | 2004-06-28 | 2012-10-31 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | ４，６位で二置換されたピリミジン及びプロテインキナーゼインヒビターとしてのそれらの使用 |
| WO2006040520A1 (en) * | 2004-10-12 | 2006-04-20 | Astrazeneca Ab | Quinazoline derivatives |
| US7947676B2 (en) | 2004-12-14 | 2011-05-24 | Astrazeneca Ab | Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents |
| MX2007010399A (es) * | 2005-02-26 | 2007-09-25 | Astrazeneca Ab | Derivados de quinazolina en la forma de inhibidores de cinasa de tirosina. |
| JP2006347936A (ja) * | 2005-06-15 | 2006-12-28 | Bayer Cropscience Ag | 殺虫性ベンズアニリド類 |
| JP2009508918A (ja) | 2005-09-20 | 2009-03-05 | アストラゼネカ アクチボラグ | 癌治療のためのｅｒｂＢ受容体チロシンキナーゼ阻害剤としての４−（１Ｈ−インダゾール−５−イル］アミノ）キナゾリン化合物 |
| GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| DE602006009968D1 (de) | 2005-11-15 | 2009-12-03 | Array Biopharma Inc | N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten |
| EP1957499A1 (en) | 2005-12-02 | 2008-08-20 | AstraZeneca AB | 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors |
| CN101003514A (zh) | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
| EP1994024A2 (en) * | 2006-03-02 | 2008-11-26 | AstraZeneca AB | Quinoline derivatives |
| UY30183A1 (es) * | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| US20070231298A1 (en) * | 2006-03-31 | 2007-10-04 | Cell Genesys, Inc. | Cytokine-expressing cancer immunotherapy combinations |
| AU2006345660A1 (en) | 2006-06-01 | 2007-12-06 | Japan As Represented By Director General Of Agency Of National Cancer Center | Tumor suppressor |
| EP1921070A1 (de) * | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| WO2008095847A1 (de) * | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| CN101878203A (zh) | 2007-10-29 | 2010-11-03 | 纳科法尔马有限公司 | 作为抗癌剂的新的4-(四唑-5-基)喹唑啉衍生物 |
| WO2009098061A1 (de) * | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| WO2009138781A1 (en) * | 2008-05-13 | 2009-11-19 | Astrazeneca Ab | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline |
| US20110160249A1 (en) | 2008-05-23 | 2011-06-30 | Schaab Kevin Murray | 5-lipoxygenase-activating protein inhibitor |
| US8648191B2 (en) * | 2008-08-08 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
| US8546431B2 (en) | 2008-10-01 | 2013-10-01 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| EP2241565A1 (en) | 2009-01-15 | 2010-10-20 | Universität Leipzig | Aurora kinase inhibitors compounds |
| CA2758030C (en) | 2009-01-16 | 2019-01-08 | Exelixis, Inc. | Malate salt of n-(4-{[6,7-bis(methyloxy)quin0lin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| KR101806323B1 (ko) | 2009-11-13 | 2017-12-07 | 다이이치 산쿄 유럽 게엠베하 | Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법 |
| US20120156130A1 (en) | 2010-08-06 | 2012-06-21 | Thore Hettmann | Use of her3 binding agents in prostate treatment |
| KR20130016041A (ko) * | 2011-08-04 | 2013-02-14 | 재단법인 의약바이오컨버젼스연구단 | 신규한 아닐린 유도체 및 이의 용도 |
| CN102603496A (zh) * | 2011-09-26 | 2012-07-25 | 盘锦兴福化工有限公司 | 2,3—二氟苯丁醚的合成方法 |
| HUE034490T2 (en) | 2013-09-16 | 2018-02-28 | Astrazeneca Ab | Therapeutic polymer nanoparticles and methods for their preparation and use |
| UY36547A (es) | 2015-02-05 | 2016-06-01 | Bayer Cropscience Ag | Derivados heterocíclicos condensados bicíclicos sustituidos por 2-(het)arilo como pesticidas |
| CA2981886A1 (en) * | 2015-04-16 | 2016-10-20 | Icahn School Of Medicine At Mount Sinai | Ksr antagonists |
| JP6913076B2 (ja) | 2015-08-07 | 2021-08-04 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 有害生物防除剤としての２−（ヘタ）アリール−置換縮合ヘテロ環誘導体 |
| CN105461642B (zh) * | 2015-12-03 | 2017-03-22 | 中国人民解放军南京军区南京总医院 | 一种新型喹唑啉衍生物lu1505及其制备方法和应用 |
| CN105418517B (zh) * | 2015-12-03 | 2017-03-22 | 中国人民解放军南京军区南京总医院 | 一种新型喹唑啉衍生物lu1509及其制备方法和应用 |
| CN105399689B (zh) * | 2015-12-03 | 2017-03-01 | 中国人民解放军南京军区南京总医院 | 一种新型喹唑啉衍生物lu1503及其制备方法和应用 |
| CN108358798A (zh) * | 2018-02-12 | 2018-08-03 | 黑龙江鑫创生物科技开发有限公司 | 一种微通道反应器合成厄洛替尼中间体的方法 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3266990A (en) * | 1963-09-24 | 1966-08-16 | Warner Lambert Pharmaceutical | Derivatives of quinazoline |
| JPS5538325A (en) * | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
| US4343940A (en) * | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
| GB2160201B (en) * | 1984-06-14 | 1988-05-11 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
| EP0326307B1 (en) * | 1988-01-23 | 1994-08-17 | Kyowa Hakko Kogyo Co., Ltd. | Novel pyridazinone derivatives and pharmaceutical preparations containing them |
| IL89029A (en) * | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
| EP0529048A4 (en) * | 1991-02-22 | 1994-08-17 | Calgene Inc | Seed plant fatty acyl reductase proteins and genes |
| EP0584222B1 (en) * | 1991-05-10 | 1997-10-08 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| NZ243082A (en) * | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| GB9323290D0 (en) * | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| GB9314884D0 (en) * | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
| GB9314893D0 (en) * | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| CA2148082A1 (en) * | 1993-09-03 | 1995-03-09 | Daisuke Machii | Imidazoquinazoline derivatives |
| GB9325217D0 (en) * | 1993-12-09 | 1994-02-09 | Zeneca Ltd | Pyrimidine derivatives |
| US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) * | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5736534A (en) * | 1994-02-23 | 1998-04-07 | Pfizer Inc. | 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents |
| WO1995024190A2 (en) * | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| ES2109796T3 (es) * | 1994-05-03 | 1998-01-16 | Ciba Geigy Ag | Derivados de pirrolopirimidilo con efecto antiproliferante. |
| TW414798B (en) * | 1994-09-07 | 2000-12-11 | Thomae Gmbh Dr K | Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation |
| GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| TW321649B (OSRAM) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| WO1996029331A1 (de) * | 1995-03-20 | 1996-09-26 | Dr. Karl Thomae Gmbh | Imidazochinazoline, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| CA2216796C (en) * | 1995-03-30 | 2003-09-02 | Pfizer Inc. | Quinazoline derivatives |
| JP4249804B2 (ja) * | 1995-04-03 | 2009-04-08 | ノバルティス・アクチエンゲゼルシャフト | ピラゾール誘導体およびその製造法 |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
| GB9508537D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| EP0824525B1 (en) * | 1995-04-27 | 2001-06-13 | AstraZeneca AB | Quinazoline derivatives |
| IL117923A (en) * | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| ATE182148T1 (de) * | 1995-05-12 | 1999-07-15 | Neurogen Corp | Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden |
| ATE247469T1 (de) * | 1995-06-07 | 2003-09-15 | Pfizer | Heterocyclische kondensierte pyrimidin-derivate |
| WO1996040648A1 (en) * | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Quinazolines and pharmaceutical compositions |
| KR100437582B1 (ko) * | 1995-07-06 | 2004-12-17 | 노파르티스 아게 | 피롤로피리미딘및그들의제조방법 |
| GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| AR004010A1 (es) * | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| GB9520822D0 (en) * | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
| CN1168138A (zh) * | 1995-11-14 | 1997-12-17 | 法玛西雅厄普约翰公司 | 芳基和杂芳基嘌呤化合物 |
| US5760041A (en) * | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
-
1995
- 1995-10-27 TW TW084111357A patent/TW321649B/zh not_active IP Right Cessation
- 1995-11-08 AT AT95936044T patent/ATE175962T1/de active
- 1995-11-08 DK DK95936044T patent/DK0790986T3/da active
- 1995-11-08 AU AU38130/95A patent/AU703328B2/en not_active Ceased
- 1995-11-08 DE DE69507505T patent/DE69507505T2/de not_active Expired - Lifetime
- 1995-11-08 EP EP95936044A patent/EP0790986B1/en not_active Expired - Lifetime
- 1995-11-08 NZ NZ294917A patent/NZ294917A/xx not_active IP Right Cessation
- 1995-11-08 ES ES95936044T patent/ES2128092T3/es not_active Expired - Lifetime
- 1995-11-08 US US08/836,362 patent/US5821246A/en not_active Expired - Lifetime
- 1995-11-08 JP JP51581696A patent/JP4011109B2/ja not_active Expired - Fee Related
- 1995-11-08 MX MX9702956A patent/MX9702956A/es unknown
- 1995-11-08 CA CA002200871A patent/CA2200871C/en not_active Expired - Fee Related
- 1995-11-08 WO PCT/GB1995/002606 patent/WO1996015118A1/en not_active Ceased
- 1995-11-12 IL IL11595995A patent/IL115959A/en not_active IP Right Cessation
-
1997
- 1997-05-07 FI FI971970A patent/FI119933B/fi not_active IP Right Cessation
- 1997-05-09 NO NO972152A patent/NO307178B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FI119933B (fi) | 2009-05-15 |
| WO1996015118A1 (en) | 1996-05-23 |
| JP4011109B2 (ja) | 2007-11-21 |
| IL115959A (en) | 2004-06-20 |
| EP0790986B1 (en) | 1999-01-20 |
| NO972152D0 (no) | 1997-05-09 |
| JPH10508616A (ja) | 1998-08-25 |
| FI971970A0 (fi) | 1997-05-07 |
| IL115959A0 (en) | 1996-01-31 |
| DE69507505T2 (de) | 1999-06-02 |
| EP0790986A1 (en) | 1997-08-27 |
| ES2128092T3 (es) | 1999-05-01 |
| AU703328B2 (en) | 1999-03-25 |
| TW321649B (OSRAM) | 1997-12-01 |
| CA2200871C (en) | 2008-08-19 |
| DE69507505D1 (de) | 1999-03-04 |
| AU3813095A (en) | 1996-06-06 |
| NO972152L (no) | 1997-05-12 |
| FI971970A7 (fi) | 1997-05-07 |
| NO307178B1 (no) | 2000-02-21 |
| CA2200871A1 (en) | 1996-05-23 |
| US5821246A (en) | 1998-10-13 |
| NZ294917A (en) | 1999-02-25 |
| ATE175962T1 (de) | 1999-02-15 |
| MX9702956A (es) | 1997-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0790986T3 (da) | Anilinderivater | |
| ATE334973T1 (de) | Chinazolinverbindungen | |
| TW345575B (en) | Pharmaceutical composition comprising an inhibitor for ras farnesylation and the preparation of the inhibitor compound | |
| DE69512930D1 (de) | Stilben-derivate verwendbar als cyclooxygenase-2 hemmer | |
| DE69729946D1 (de) | Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia | |
| DK0711280T3 (da) | Perhydroisoindolderivater, fremstilling af disse forbindelser og farmaceutiske præparater indeholdende disse forbindelser | |
| PL326203A1 (en) | (methylsulphonyl)phenyl-2-(5)-furanones as cox-2 inhibitors | |
| DE69733008D1 (de) | Chinazolinderivate als antitumormittel | |
| DE69213451D1 (de) | Fluoralkoxybenzylaminoderivate stickstoffhaltiger heterocyclen | |
| ATE212343T1 (de) | 3,4-diaryl-2-hydroxy-2,5-dihydrofurane als wirkstoffvorstufen von cox-2 inhibitoren | |
| DK0766696T3 (da) | Thiazolidinderivater, fremstilling af disse forbindelser og lægemidler indeholdende disse forbindelser | |
| DK0874812T3 (da) | Hidtil ukendte 2,3,5-trimethyl-4-hydroxyanilidderivater, fremstilling deraf og terapeutisk anvendelse deraf | |
| DE69730837D1 (de) | Indolderivate zur behandlung von osteoporose | |
| BRPI0407841A (pt) | inibidores heterocìclicos de quinase | |
| ATE214390T1 (de) | Hydroisochinolinderivate | |
| DK0604186T3 (da) | HIV-proteaseinhibitorer, som er egnede til behandling af AIDS | |
| DK0823909T3 (da) | Hidtil ukendte heterocykliske forbindelser | |
| MX9303605A (es) | Derivados de azabicicloheptano n-substituidas, su obtencion y uso. | |
| DE59108566D1 (de) | Heteroarylmethylbenzole-Aromatasehemmer | |
| DK0674521T3 (da) | Fremgangsmåde til behandling af kronisk prostatitis med 17beta-N-tertbutylcarbamoyl-4-aza-5a-andost-1-en-3-on | |
| DK0675895T3 (da) | Etoposidderivater, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemiddel og anvendelse deraf til fremstilling af et lægemiddel til anticancerbehandling | |
| ATE154352T1 (de) | Indolderivate als steroid 5-alpha-reduktase inhibitoren | |
| DK0766695T3 (da) | Pyrrolidinderivater til behandling af CCK- og gastrinrelaterede sygdomme |